Compare · JNJ vs MPLT
JNJ vs MPLT
Side-by-side comparison of Johnson & Johnson (JNJ) and MapLight Therapeutics Inc. (MPLT): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both JNJ and MPLT operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- JNJ is the larger of the two at $680.19B, about 1521.9x MPLT ($446.9M).
- Over the past year, JNJ is up 41.6% and MPLT is down 50.7% - JNJ leads by 92.3 points.
- JNJ has been more active in the news (14 items in the past 4 weeks vs 9 for MPLT).
- JNJ has more recent analyst coverage (25 ratings vs 15 for MPLT).
- Company
- Johnson & Johnson
- MapLight Therapeutics Inc.
- Price
- -
- -
- Market cap
- $680.19B
- $446.9M
- 1M return
- +10.60%
- -9.91%
- 1Y return
- +41.60%
- -50.75%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NASDAQ
- IPO
- 2025
- News (4w)
- 14
- 9
- Recent ratings
- 25
- 15
Johnson & Johnson
Johnson & Johnson researches and develops, manufactures, and sells a range of products in the health care field worldwide. It operates through three segments: Consumer Health, Pharmaceutical, and Medical Devices. The Consumer Health segment offers baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR. CI:LABO, NEUTROGENA, and OGX brands; acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; smoking cessation products under the NICORETTE brand; and acid reflux products under the PEPCID brand. This segment also provides women's health products, such as sanitary pads and tampons under the STAYFREE, CAREFREE, and o.b. brands; wound care products comprising adhesive bandages under the BAND-AID brand; and first aid products under the NEOSPORIN brand. The Pharmaceutical segment offers products in various therapeutic areas, including immunology, infectious diseases, neuroscience, oncology, pulmonary hypertension, and cardiovascular and metabolic diseases. The Medical Devices segment provides electrophysiology products to treat cardiovascular diseases and neurovascular care products to treat hemorrhagic and ischemic stroke; orthopaedics products in support of hips, knees, trauma, spine, sports, and other; advanced and general surgery solutions that focus on breast aesthetics, ear, nose, and throat procedures; and disposable contact lenses and ophthalmic products related to cataract and laser refractive surgery under the ACUVUE brand. The company markets its products to general public, and retail outlets and distributors, as well as distributes directly to wholesalers, hospitals, and health care professionals for prescription use. Johnson & Johnson was founded in 1886 and is based in New Brunswick, New Jersey.
Latest JNJ
- Johnson & Johnson to acquire Ollin Biosciences and late-stage bispecific antibody with best-in-class potential in ophthalmology
- EVP, Chief Legal Officer Forminard Elizabeth exercised 13,072 shares at a strike of $151.41 and sold $3,717,546 worth of shares (13,072 units at $284.39) (SEC Form 4)
- FDA Approval for LAZCLUZE issued to JANSSEN BIOTECH
- Johnson & Johnson Announces CAPLYTA (lumateperone) Shows Significant and Rapid Improvement in Bipolar Mania in Second Pivotal Phase 3 Study
- Raised Outlooks and a Cancer Approval Arrive in the Middle of Medicare Open Enrollment
- Johnson & Johnson announces ICOTYDE® (icotrokinra) delivers significant improvement in psoriatic arthritis disease activity among biologic-naive patients with once-daily targeted oral peptide
- Johnson & Johnson announces new Phase 2 nipocalimab study data in Sjögren's disease that reveal insights on importance of symptom improvements most valued by patients
- FDA Approval for RYBREVANT FASPRO issued to JANSSEN BIOTECH
- Johnson & Johnson announces U.S. FDA Approval of RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) as First and Only Dual-Targeted Therapy for Advanced Head and Neck Cancer
- Data Show Positive Survival and Patient Outcomes with Best-Practice Impella Support in HRPCI, in Contrast to CHIP-BCIS3 Study Results
Latest MPLT
- Amendment: SEC Form SCHEDULE 13G/A filed by MapLight Therapeutics Inc.
- MapLight Therapeutics Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits
- SEC Form S-3 filed by MapLight Therapeutics Inc.
- SEC Form POS AM filed by MapLight Therapeutics Inc.
- Amendment: SEC Form SCHEDULE 13G/A filed by MapLight Therapeutics Inc.
- SEC Form 10-Q filed by MapLight Therapeutics Inc.
- MapLight Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits
- MapLight Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Update
- MapLight Therapeutics to Participate in Upcoming Investor Conference
- Chief Discovery Officer Kreitzer Anatol sold $96,024 worth of Voting Common Stock (12,248 units at $7.84) (SEC Form 4)